Press ReleaseAIMHI_wpuser2024-08-29T11:16:30+00:00

Press Release

Press Release

First in the World! Arbele’s CDH17xCD3 Bispecific Antibody Received Clinical Trial Phase I Ethics Approval in Australia

AIMHI_wpuser2025-02-21T15:59:41+00:00April 17, 2022|Press Release|

2021 Highlights: Thank You for Supporting AIM-HI to Accelerate a Cure!

AIMHI_wpuser2025-02-21T15:59:42+00:00December 22, 2021|Press Release|

Applications Open for the 2022 AIM-HI Women’s Venture Competition!

AIMHI_wpuser2025-02-21T15:59:42+00:00December 15, 2021|Press Release|

Celebrating Progress in Cancer Research and Entrepreneurship!

AIMHI_wpuser2025-02-21T15:59:42+00:00September 24, 2021|Press Release|

2021 Women’s Venture Competition Announced Semi-Finalists!

AIMHI_wpuser2025-02-21T15:59:42+00:00July 19, 2021|Press Release|

Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs

AIMHI_wpuser2025-02-21T15:59:42+00:00June 23, 2021|Press Release|

Previous 567 Next

AIMhi

AIM-HI Accelerator Fund is a 501(c)(3) tax-exempt nonprofit organization.

Tax ID #: 82-4322538

Address:

5515 Security Lane, Suite 1105
Rockville, MD 20852

Email:

info@aim-hiaccelerator.org

Phone:

1-800-321-CURE (2873)

what we do

Copyright © AIM-HI 2025 All Rights Reserved

AIMhi

AIM-HI Accelerator Fund is a 501(c)(3) tax-exempt nonprofit organization.

Tax ID #: 82-4322538

Copyright © AIM-HI 2025 All Rights Reserved